ABO Blood Group Profile Frequencies and Relationship in COVID-19 Disease Susceptibility and Severity in Lagos, Nigeria

Nkiruka Nnoyelum Oduukwe¹, Ngozi Mirabel Otuonye²*, Adeola Oladunni Adebayo³, Mercy Mayowa Ojetunde², Iwalokun Bamidele², Joy Boluwatife Ayoola², Chidinma Gab-Okafor⁴, Susan Abba Holdbrooke⁵, Emelda Chukwu⁶, Mabel Uwandu⁶, Itse Yusuf Nyam², Oliver Ezechi¹, Gregory Ohihoin¹, Akinola Abayomi⁶, Akin Osibogun⁷, Abimbola Bowale⁸, Bodunrin Osikomaiya⁸, Babafemi Thomas⁸, Bamidele Mutiu⁸ and Babatunde Lawal Salako²

¹Clinical Science Department Nigerian Institute of Medical Research, Yaba
²Central Research Laboratory, Nigerian Institute of Medical Research, Yaba, Lagos
³Federal Neuro-Psychiatric Hospital Yaba Lagos, Nigeria
⁴Biochemistry and Nutrition department, Nigerian Institute of Medical Research, Yaba
⁵Centre for Human Virology and Genomics, Nigerian Institute of Medical Research, Yaba, Lagos
⁶College of Medicine University of Lagos, Nigeria
⁷Lagos State Primary Health Care Board, Lagos, Nigeria
⁸Mainland Infectious Disease Hospital, Yaba, Lagos

*Corresponding author: Ngozi Mirabel Otuonye, Central Research Laboratory, Nigerian Institute of Medical Research, PMB 2013, Yaba, Lagos Nigeria

ARTICLE INFO

Received: January 27, 2022
Published: February 07, 2022

Citation: Nkiruka N, Ezechi O, Ohihoin G, Ngozi M, Itse Y, et al. ABO Blood Group Profile Frequencies and Relationship in COVID-19 Disease Susceptibility and Severity in Lagos, Nigeria. Biomed J Sci & Tech Res 41(4)-2022. BJSTR. MS.ID.006642.

ABSTRACT

Introduction: Globally, studies have shown conflicting results regarding the association of blood groups with SARS CoV-2 infection. The novel coronavirus SARS-CoV-2 is causing COVID-19 severe cases leading to hospitalization of some people while others experience moderate to mild symptoms. The aim of this study is to investigate the role of ABO blood group in COVID-19 disease susceptibility and severity in Nigeria.

Methods: This study is a case series that includes patients that are evaluated between June and August 30, 2020, and diagnosed with COVID-19. ABO blood grouping was done on the COVID-19 samples to known the blood type associated with mild to severe cases of COVID-19. Hospitalization and death were evaluated for association with blood type.

Results: The total number of COVID-19 patients enrolled was 697, 66.1% male and the mean age 41.3 ±12.9 years. Most were symptomatic [56.4%] and mortality rate was 1.3%. The most common symptoms were dry cough [27.5%], fever [26.5%] and breathing difficulty [18.5%]. Co-morbidities were also present in [24.0%] of the study participants. Blood group profile shows group O [59.25%] to be more prevalent than group A [22.2%], and B [15.10%] and AB [3.44%] being the least. The blood group that showed association with severe covid-19 diseases were: B, A and O [10.5%, 9.0%] and 8.5%]. There seem to be no significant difference between the severity of SARS-CoV-2 and the blood group profiles.
**Introduction**

COVID-19 caused by the Severe Acute Respiratory Syndrome Coronavirus-2 [SARS-CoV-2] was first described as a serious infection leading to significant morbidity and mortality in Wuhan, China in January 2020 [Zhao, et al. [1]]. The number of deaths was increasing due to the catastrophic effect of the emerging new strains. Research has shown that there are predicting factors of COVID-19 severity such as demographic, clinical, immunologic, haematological, biochemical, and radiographic factors [Benjamin, et al. [2]]. According to Samra, et al. [3] ABO groups can play a role in COVID-19 severity and susceptibility. The rapid global spread of the novel coronavirus SARS-CoV-2 has strained existing healthcare and testing resources, and it is causing COVID-19 severe cases in some people than in others. While some people experience only mild symptoms, others are being hospitalized [Samra, et al. [3]]. The pathogenesis of severe COVID-19 and the associated respiratory failure are still unclear, but the higher mortality rate is consistently associated with older age and being male [Samra, et al. [3]]. Many studies have shown that the ABO blood type is a potential risk for various diseases such as cancer, myocardial infarction, acute kidney injury, and venous thromboembolism [Dentali, et al. [4,5]].

Apart from comorbidities and other predicting factors, findings have shown that the ABO blood group has a correlation with COVID-19 susceptibility and severity. Biological factors that determine susceptibility to SARS-CoV-2 and severity of COVID-19 are yet to be fully understood [Samra, et al. [3]]. The ABO blood grouping may influence the susceptibility of COVID-19 and severity of the disease [Zhao, et al. [6]]. As reported by Nagla, et al. [7], patients from three hospitals in Wuhan, Shenzhen, and China showed the likelihood of association between ABO blood groups and the susceptibility to COVID-19 exposure after the outbreak of the COVID-19 infection. The study results showed that individuals with blood group A had a markedly greater risk of COVID-19 exposure, while those with blood group O had a significantly reduced risk of COVID-19 infection. In a meta-analysis of two different case-control cohorts, blood group A was reported to confer a greater risk of aggravated COVID-19, while blood group O offer protection against COVID-19 infection [WU, et al. [8]].

However, A, B and O blood group are antigenic complex oligosaccharide molecules located on the extracellular surface of the red blood cell membrane [Storry JR, et al. [9]]. ABO blood group are also expressed on the surface of other human cells and tissues, including the epithelium, sensory neurons, platelets, and the vascular endothelium [Eastlund [10]]. The ABO blood group have been reported to play a key role in various human diseases such as diabetes, cardiovascular, neoplastic, carcinoma and other infectious disorders [Cheng et al. [11-13]]. ABO and Rh blood groups polymorphism are valuable and indispensable tools in contemporary medicine, population genetics and anthropology. The distribution of these two blood groups has been reported different populations of the world and they showed considerable variation in different geographic locations, reflecting the underlying genetic and ethnic diversity of human populations [Garraty ,et al. [14,15]].

Research has shown that there are predicting factors of COVID-19 severity from this preliminary report. However, the patients having blood group B may have a higher risk of persistent positivity having the highest prevalence among those who had moderate SARS-CoV-2 disease [41.9%]. Further studies on the individuals with confirmed exposure to COVID-19 infection may reveal better association.

**Keywords:** COVID-19; SARS-CoV-2; ABO Blood Group Profile; Nigeria

---

**Conclusion:**

There is no statistical significance between the blood group profiles in association with SARS CoV-2 severity from this preliminary report. However, the patients having blood group B may have a higher risk of persistent positivity having the highest prevalence among those who had moderate SARS-CoV-2 disease [41.9%]. Further studies on the individuals with confirmed exposure to COVID-19 infection may reveal better association.

**Keywords:** COVID-19; SARS-CoV-2; ABO Blood Group Profile; Nigeria
Methods

Study Design and Participants

This study is a case series that includes patients that are evaluated between June and August 30, 2020, and diagnosed with COVID-19. With ethical approval obtained from the Institutional Review Board [IRB] at the Nigerian Institute of Medical Research [NIMR], Yaba, Lagos, Nigeria, patient data were obtained and reviewed at the Mainland Infectious Disease Hospital and the Nigerian Institute of Medical Research, Yaba. Informed consent was also obtained from the study participants before their health records were obtained. They were confirmed to have been infected with SARS-CoV-2 by a positive reverse transcriptase polymerase chain reaction test [Qpcr] of nasopharyngeal, throat and blood samples. Clinical outcomes were also monitored and recorded.

Data Collection and Statistical Analysis: Clinicians and trained research assistants retrospectively reviewed and copied patients’ health records out to a standardized data collection form. Health records copied out include demographic information, signs and symptoms presented with, co-morbidities, and patient outcome. A formal sample size was not calculated for this study because the objective of the study was to describe the clinical characteristics of the patients and their Blood group profile of participants who had enough information in their health records for analysis. Records were double entered into the forms before merging to reduce errors during data entry. Descriptive analyses were performed using Statistical Package for the Social Science [SPSS] version 25 [IBM, USA].

Results

A total of 697 COVID-19 patients were included in this study. The mean age [S.D] of the study participants is 41.32 [12.917]. COVID-19 was common in males [66.1%) than in females [33.9%]. Out of the 697 participants, 43.6% were asymptomatic while 56.4% were symptomatic showing symptoms like breathing difficulty, fever, dry cough, running nose, sore throat and others as shown on Tables 1 & 2. The most frequently detected blood group in the population was O accounting for [59.2%], followed by A 155[22.2%], B 105[15.10%] and the least is AB 24[3.4%]. Figure 1 showed the blood groups that accounted for COVID-19 severity: blood group B 11 [10.5%] followed by A 14 [9.0%], O 35 [8.5%] and AB 1 [4.2%]. There was no significant statistical difference between the blood groups in relation to COVID-19 severity [p=0.358].

Table 1: Baseline Characteristics and Symptoms of COVID-19 among the Patients.

| Baseline Characteristics | Age | Frequency (%) n=697 (100) |
|--------------------------|-----|--------------------------|
| Mean (S.D)               | 41.32 (12.917) |                           |
| Range (Minimum – Maximum)| 1-83            |                           |
| Gender                   |                 |                           |
| Male                     | 461 (66.1)     |                           |
| Female                   | 236 (33.9)     |                           |
| Symptomatology           |                 |                           |
| Asymptomatic             | 304 (43.6)     |                           |
| Symptomatic              | 393 (56.4)     |                           |
| Patient Outcome          |                 |                           |
| Dead                     | 9 (1.3)        |                           |
| Survived                 | 688 (98.7)     |                           |

Figure 1: Profile of Blood Groups and Percentage of SARS-CoV-2 Disease Conditions.
Table 2: Symptomatic patients (56.4%). The most common symptoms were: dry cough (27.5%), Fever 185 (26.5) and breathing difficulty (18.5%).

| Symptom               | Yes  | No  |
|-----------------------|------|-----|
| Breathing Difficulty  |      |     |
| Yes                   | 129  | 568 |
| No                    | 512  |     |
| Fever                 | 185  | 512 |
| Nasal Congestion      |      |     |
| Yes                   | 22   | 675 |
| No                    | 658  |     |
| Dry Cough             |      |     |
| Yes                   | 192  | 505 |
| No                    | 568  |     |
| Running Nose          |      |     |
| Yes                   | 28   | 669 |
| No                    | 669  |     |
| Diarrhoea             |      |     |
| Yes                   | 44   | 653 |
| No                    | 653  |     |
| Abdominal Pain        |      |     |
| Yes                   | 36   | 661 |
| No                    | 661  |     |
| Malaise               |      |     |
| Yes                   | 123  | 574 |
| No                    | 574  |     |
| Sore Throat           |      |     |
| Yes                   | 72   | 635 |
| No                    | 635  |     |
| Joint Pain            |      |     |
| Yes                   | 38   | 659 |
| No                    | 659  |     |
| Loss of Appetite      |      |     |
| Yes                   | 57   | 640 |
| No                    | 640  |     |
| Chest Pain            |      |     |
| Yes                   | 81   | 616 |
| No                    | 616  |     |
| Loss of Smell         |      |     |
| Yes                   | 77   | 620 |
| No                    | 620  |     |
| Loss of Taste         |      |     |
| Yes                   | 48   | 649 |
| No                    | 649  |     |
| Headache              |      |     |
| Yes                   | 45   | 652 |
| No                    | 652  |     |

Tables 3 & 4 showed five [5] persons having blood group O were among the deceased [55.6%]. Four out of the 5 deceased had severe COVID-19 and were males. Their age, ranged from 53 to 65 years. The youngest being 53 years was a woman who had a mild symptom of COVID-19. Three [3] women having blood group A were among the deceased [33.3%]. Aged ranged 66-75 years. Two out of these three women had mild cases and one severe COVID-19 case. This is a proof to show that old age and co morbidities are risk factors to COVID-19 disease complications and death. Five [5/ 55.6%] persons having blood group O were among the deceased four out of the 5 deceased had severe COVID-19 and were males and aged 53 to 65 years. The youngest being 53 years was a woman who had a mild symptom of COVID-19. Three [3/ 33.3%] women having blood group A were among the deceased. Their age ranged from 66 to 75.

Table 3: Co-Morbidities in covid-19 patients at presentation, N = 697.

| Symptoms                              | Yes  | No  |
|---------------------------------------|------|-----|
| Malaria                               | 5    | 692 |
| No                                    | 692  |     |
| Pneumonia                             | 7    | 690 |
| No                                    | 690  |     |
| Hypertension                          | 99   | 598 |
| No                                    | 598  |     |
| Cancer                                | 3    | 694 |
| No                                    | 694  |     |
| Chronic Obstructive Pulmonary Disease (COPD) | 2    | 695 |
| No                                    | 695  |     |
| Diabetes                              | 41   | 656 |
| No                                    | 656  |     |
| Asthma                                | 6    | 691 |
| No                                    | 691  |     |
| Congestive Cardiac Failure            | 5    | 692 |
| No                                    | 692  |     |
| Lower Respiratory Tract Infection (LRTI) | 5    | 692 |
| No                                    | 692  |     |
| Tuberculosis                          | 2    | 695 |
| No                                    | 695  |     |
Table 4: Blood Group Disease Condition Cross Tabulation and Percentages.

| Disease Condition | Blood group A | Blood group B | Blood group AB | Blood group O | Chi square | P value |
|-------------------|---------------|---------------|----------------|---------------|------------|---------|
| Mild              | 82 (52.9)     | 50 (47.6)     | 15 (62.5)      | 246 (59.6)    | 6.610      | 0.358   |
| Moderate          | 59 (38.1)     | 44 (41.9)     | 8 (28.6)       | 132 (31.9)    |            |         |
| Severe            | 14 (9.0)      | 11 (10.5)     | 1 (4.2)        | 35 (8.5)      |            |         |
| Total             | 155 (100)     | 105 (100)     | 24 (100)       | 413 (100)     |            |         |

Discussion

A person’s blood group [A, B, AB and O] is determined by the presence or absence of specific antigens on red blood cells which trigger an immune response. Reports from some recent studies, suggest that ABO blood group may play a role in the immunopathogenesis of COVID-19 disease with group A conferring a higher susceptibility to infection and or severe disease and group O individuals less likely to test positive (Geol, et al. [26]) and Fan, et al [27]. However, reports are in contrast to our current study which shows no statistical significant evidence [p = 0.358] that individuals with the blood group profile A were associated with increased risk to severe cases of COVID-19. Furthermore, in moderate cases of Covid-19 infection, group B [41.9%] individuals were more represented and may have increased risk to COVID-19 susceptibility when compared to other blood groups. We also observed that most of the deceased persons [5/ 55.6%] had blood group O, were males and age 53 to 65 years. Three [3 / 33.3%] women having blood group A were equally among the deceased aged 66 to 75 years with co-morbidities which include Pneumonia, Diabetes, LRTI, Hypertension in both severe and mild cases confirming that both age and comorbidities can lead to death with COVID-19 disease.

A recent study that supported our data reported that a significantly increased risk was associated with blood group B Almadhi, et al. [28], which is also comparable to findings by Latz, et al. [29] and meta-analysis by Liu, et al. [30]. In Nigeria and other parts of the globe, blood group O Rhesus positive has consistently been the most common, followed by A, then B, and AB being the least [Anifoweshe et al 2016]. According to [Geol et al 2021], group O originated in Africa before early human migration, and has anti-A and/or anti-B antibodies present in group O individuals which binds to the corresponding antigens on the viral envelope and contribute to viral neutralization, thereby conferring some protection by preventing target cell infection. However, our data proposed that group B and or O individuals may be more likely to be infected with COVID-19 disease suggesting that COVID-19 in Nigeria and few other studies from other parts of the world may not be affected by the anti A or B that has been proposed to confer protection to those that have it. Furthermore, ABO blood group is determined by inheritance, natural selection, showing underlying genetic and ethnic diversity which may have influenced the current frequencies of ABO types among Nigerian populations based on susceptibility to particular diseases or disorders. Hospitalization, higher infection chances, and death were found among those with blood group A and O, and ethnicity was also a factor considered to weigh COVID-19 risks in this study.

Conclusion

The ABO blood group was not associated with the presentation and recovery period of COVID-19 disease during the period of this study. However, the patients of blood group B profile seem to have higher risk of COVID-19 disease susceptibility. To further detect the susceptibility and severity of COVID-19 infection, more samples of individuals with confirmed exposure to COVID-19 infection should be conducted.

Availability of Supporting Data

Besides those presented in the study, there are no other supporting data for this manuscript.

Competing Interests

The authors report no competing (commercial/academic) interests.

Ethical Approval

Approval to conduct this study was received from the Institutional Review Board (IRB) at NIMR, Yaba, Lagos.

Funding

This study was funded by the Nigerian Institute of Medical Research, NIMR (Grant Number: NMG-CIF-06-0024). The PI and co-authors financed this study.

Acknowledgment

We acknowledge the director general and CEO of the Nigerian Institute of Medical Research (NIMR) for providing enabling environment for this study.
References

1. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, et al. (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798): 270-273.

2. Benjamin Gallo Marin, Ghazal Aghagoli, Katya Lavine, Lanbo Yang, Emily J Siff, et al. (2021) Predictors of COVID-19 severity. A literature review. Rev Med Virol 31(1): 1-10.

3. Samra S, Habeib M, Nafee R (2021) ABO groups can play a role in susceptibility and severity of COVID-19. The Egyptian Journal of Bronchology 15(1): 9.

4. Dentafi F, Sironi AP, Ageno W, Turato S, Bonfanti C, et al. (2012) Non-O blood type is the commonest genetic risk factor for VTE; results from a meta-analysis of the literature. Semin Thromb Hemost 38(5): 535-548.

5. Sun W, Wen CP, Lin J, Wen C, Pu X, et al. (2015) ABO blood types and cancer risk - a cohort study of 339,432 subjects in Taiwan. Cancer Epidemiol 39(2): 150-156.

6. Zhao J, Yang Y, Huang H, Li D, Gu D, et al. (2020) Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin Infect Dis (2021): 328-331.

7. Nagla AES, Manal EI H, Ahlam AA, Basma G Ed, Thikryat Neamatahlah, et al. (2021) The Impact of ABO Blood Grouping on COVID-19 Vulnerability and Seriousness: A Retrospective Cross-Sectional Controlled Study among the Arab Community. Int J Environ Res Public Health 18(1): 276.

8. Wu B, Gu D, Yang YJ, Jie Yang, Wang Qin Shen (2020) Association between ABO blood groups and COVID-19 infection, severity and demise. A systematic review and meta-analysis. Infect Genet Evol 84: 104485.

9. Storry JR, Okson ML (2009) The ABO blood group system revisited A Review and Update. Immunohematology 25(2): 48-59.

10. Eastlund T (1998) The histo-blood group. ABO system and tissue transplantation. Transfusion 38(10): 975-988.

11. Cheng Y, Cheng G, Chui CH, Lau FY, Chan PK, et al. (2005) ABO blood group and susceptibility to severe acute respiratory syndrome. JAMA 293(12): 1450-141.

12. Liambuno GM, Franchini M (2013) Beyond immunohaematology the role of the ABO blood group in human diseases. Blood Trans 11(4): 491-499.

13. Gershman B, Moreira DM, Tollesfon MK, Frank I, Cheville JC, et al. (2016 ) The association of ABO blood type with disease recurrence and mortality among patients with uterohelial carcinoma of the bladder undergoing radical cystectomy. Urol Oncol 34(1): 1-9.

14. Gurnatty G, Glynn SA, McEntire R (2004) ABO and Rh (D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion 44(5): 703-706.

15. Anifowose AT, Owooludan OA, Akinyeye KM, Iyiola OA, Oyegbemi BF (2016) Gene frequencies of ABO and Rh blood groups in Nigeria: A review. The Egyptian Journal of Medical and Human Genetics 18(3): 205-210.

16. Hamed CT, Bollaht MA, Abdelhamid M, Mahmoud M, Ba B, et al. (2012) Frequencies and ethnic distribution of ABO and Rh (D) blood groups in Mauritania: results of first nationwide study. Int J Immunogenet 39(2): 151-154.

17. Maatoghi TJ, Paridark M, Shoushtari MM, Kiani B, Nori B, et al. (2016) Distribution of ABO blood groups and rhesus factor in a Large Scale Study of different cities and ethnicities in Khuzestan province Iran. Egypt J Med Hum Genet 17(1): 105-109.

18. Tesfaye K, Petros Y, Andargie M (2015) Frequency distribution of ABO and Rh (D) blood group alleles in Silte Zone Ethiopia. Egyptian Journal of Medical Human Genetics 16(1): 71-76.

19. Ndueua ST, Noubiap JN, Nansseu JRN, Wonkam (2014) A Phenotypic and allelic Distribution of the ABO and Rhesus (D) blood groups in the Cameroonian Population. Int J Immunogenet 41(3): 206-210.

20. Boualahid S, Adouani B, Laouisina A, Mokhtari A, Abdelmajid Soulmanyami, et al. (2013) Distribution of ABO and Rhesus D blood antigens in Morocco. Int J Biol Anthropol 6(1).

21. Said N, Ben Ahmed F, Doghri A, Ghazouani E, Layouni S, et al. (2003) The ABO system polymorphism in Tunisian blood. Transfus Clin Biol 10(5): 331-334.

22. Randriamanantany ZA, Rajaonatahina DH, Razafimanantsoa FE, Rasaminirakotraoka MT, Andriamahenina R, et al. (2012) Phenotypic and allelic profile of ABO and Rhëus D blood group system among blood donor in Antananarivo. Int J Immunogenet 39(6): 477-479.

23. Loua A, Lamah MR, Haba NY, Camara M (2007) Frequency of blood groups ABO and Rhesus D in the Guinean population. Transfus Clin Biol 14(5): 435-439.

24. Dewan G (2015) Comparative frequency and allelic distribution of ABO and Rh (D) blood groups of major tribal communities of southern Bangladesh with General population and their determinants. Egypt J Med Hum Genet 16(2): 141-147.

25. Chandra T, Gupta A (2012) Frequency of ABO and rhesus blood groups in blood donors. Asian J Trans Sci 6(1): 52-53.

26. Goel R, Bloch EM, Pirenne F, Arwa Z, Ali Riyami, Elizabeth Crowe, et al. (2021) ABO blood group and COVID-19: a review on behalf of the ISBT COVID-19 working group. Vox Sang 116(6): 849-861.

27. Fan G, Zhang W, Li B, Li DJ, Zhang J, et al. (2020) Association Between ABO Blood Group System and COVID-19 Susceptibility in Wuhan. Front Cell Infect Microbiol 10: 404.

28. Almahdi M, A Abdulrahman, A Alawadhi, Ali A Rabaan, Stephen Atkin, et al. (2021) The effect of ABO blood group and antibody class on the risk of COVID-19 infection and severity of clinical outcomes. Sci Rep 11(1): 5745.

29. Latz CA, DeCarlo C, Boitano L, Png CYM, Patell R, et al. (2020) Blood type and outcomes in patients with COVID-19. Ann Hematol 99(9): 2113-2118.

30. Nanyang Liu, Tingting Zhang, Lina Ma, Huiqing Zhang, Huichan Wang, et al. (2021) The Impact of ABO Blood Grouping on COVID-19 Infection Risk and Mortality: A Systematic Review and Meta-analysis. Blood Reviews 48.

Copyright@ Ngozi Mirabel Otuonye | Biomed J Sci & Tech Res | BJSTR. MS.ID.006642.
